Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy

Curr Stem Cell Res Ther. 2024;19(6):809-819. doi: 10.2174/1574888X18666230608105703.

Abstract

Neurodegenerative disorders (NDs) including Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease are all incurable and can only be managed with drugs for the associated symptoms. Animal models of human illnesses help to advance our understanding of the pathogenic processes of diseases. Understanding the pathogenesis as well as drug screening using appropriate disease models of neurodegenerative diseases (NDs) are vital for identifying novel therapies. Human-derived induced pluripotent stem cell (iPSC) models can be an efficient model to create disease in a dish and thereby can proceed with drug screening and identifying appropriate drugs. This technology has many benefits, including efficient reprogramming and regeneration potential, multidirectional differentiation, and the lack of ethical concerns, which open up new avenues for studying neurological illnesses in greater depth. The review mainly focuses on the use of iPSC technology in neuronal disease modeling, drug screening, and cell therapy.

Keywords: disease modeling; drug screening; iPSC; neural disease; pluripotent stem cells; stem cell..

Publication types

  • Review

MeSH terms

  • Animals
  • Cell Differentiation
  • Cell- and Tissue-Based Therapy / methods
  • Disease Models, Animal
  • Drug Evaluation, Preclinical* / methods
  • Humans
  • Induced Pluripotent Stem Cells* / cytology
  • Neurodegenerative Diseases* / therapy